ImClone Systems Inc.
Shares climbed $6.97, or 18.4 percent, to $44.90 after the company said the drug Erbitux improved the survival rate of patients with the most common type of lung cancer in a late-stage study.
Stock of interest
The Baltimore Sun
Copyright
© 2021, The Baltimore Sun, a Baltimore Sun Media Group publication | Place an Ad